Jenna's experience with Nucala
Listen to Jenna, prescribed Nucala since June 2016, sharing her experience.
Severe eosinophilic asthma
Severe asthma is a complex heterogeneous disease affecting up to 10% of people with asthma.1 Depending on criteria used, 20% to 79% of patients with severe asthma have been reported as having eosinophilic inflammation 23
30–40% of patients with severe asthma require regular use of OCS 45which can result in serious and often irreversible adverse effects, including bone fractures, cataracts, bruising, muscle weakness, weight gain, cardiovascular complications and infections.678
Meet the types of patients who could benefit from Nucala
Unless otherwise noted, patient images and cases are for illustrative purposes only.
Violet, age 50, has been living with asthma for the past 15 years.
After experiencing two severe exacerbations last year, Violet has been constantly worried that it might happen again. Her fear has led to her giving up the one activity she loves most, swimming with her friends.
Judy was diagnosed with asthma seven years ago when she was 32.
Judy is concerned about taking OCS long-term. Her confidence took a hit after gaining weight due to the high dose of steroids. She thought she would at least start feeling better, but now her asthma is uncontrolled again. She feels like it has all been for nothing.
Manda was diagnosed with asthma in her mid-20s; she is now 67. She has had three exacerbations in the last year, requiring hospital stays and oral steroids.
Manda has noticed a dramatic worsening of her asthma over the past year or so. She knows how important it is to keep active as she gets older, but since suffering a severe attack while out with friends a few months ago. Manda prefers not to go too far from home.
Sara is 12 and was diagnosed 5 years ago. She had 2 exacerbations in the last year, one of which led to an ED visit.
After these attacks, Sarah missed school and her mother missed work in order to look after her. She hates having asthma attacks and gets very low, especially about missing out on things with her friends.
BID, twice daily; FEV1, forced expiratory volume in 1 second; OD, once daily; OCS, oral corticosteroid;
Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 9
- Moore WC, et al. J Allergy Clin Immunol 2007; 119:405-413.
- de Carvalho-Pinto RM, et al. Respir Med. 2012;106:47–56
- Albers FC, et al. J Asthma. 2018;55:152–160
- The ENFUMOSA Study Group. Eur Respir J. 2003;22:470–477;
- Heaney LG, et al. Thorax. 2010;65:787–794;
- Walsh LJ, et al. Thorax. 2001;56:279–284;
- Lefebvre P, et al. J Allergy Clin Immunol. 2015;136:1488–1495;
- Sarnes E,et al. Clin Ther. 2011;33:1413–1432.
- Nucala SmPC.
- Ortega HG et al. Lancet Respir Med 2016; 4:549–556.